CRISPR Therapeutics will collaborate with Massachusetts General Hospital to research the use of the CRISPR/Cas9 gene editing tool in T cell cancer therapy. Its application will address deficiencies in hematologic and solid tumours which T cells commonly attach to. By creating improved versions of these cells that work for a variety of patients and tumour types, CRISPR intends to make gene editing for T cell cancer therapies a standard practice, said GlobeNewswire, head of Immuno-oncology Research and Translation at CRISPR.
CRISPR Therapeutics will collaborate with Massachusetts General Hospital to research the use of the CRISPR/Cas9 gene editing tool in T cell cancer therapy. Its application will address deficiencies in hematologic and solid tumours which T cells commonly attach to. By creating improved versions of these cells that work for a variety of patients and tumour types, CRISPR intends to make gene editing for T cell cancer therapies a standard practice, said Jon Terrett, head of Immuno-oncology Research and Translation at CRISPR.